Experience using centralized spirometry in the phase 2 randomized, placebo-controlled, double-blind trial of denufosol in patients with mild to moderate cystic fibrosis

This was a randomized, double-blind trial designed to prospectively assess the impact of centralized spirometry in 89 patients with mild-to-moderate cystic fibrosis who were being treated with denufosol or placebo. Endpoints included FEV1, FVC and FEF25–75, which were examined using the Vitalograph Spirotrac Centralized Spirometry System.